A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

Inclusion Criteria:

• Subjects must have histologically- or cytologically-diagnosed epithelial high-gradeserous cancer of the ovary, fallopian tube cancer or primary peritoneum cancer thatis refractory to prior therapy and must have platinum-resistant disease defined as:

• Subjects who have received only 1 platinum-based chemotherapy regimen for atleast 4 cycles of platinum must have disease progression on treatment oroccurring ≤ 26 weeks after their last dose of platinum.

• Patients who have progressed following a second course of a platinum basedregimen.

• Subjects may have up to 2 additional systemic regimens for advanced ormetastatic disease. Maintenance regimens (e.g., with a PARP inhibitor orbevacizumab) are not considered separate regimens.

• Age greater than or equal to 18 years at the time of signing the informed consentform (ICF).

• Has measurable disease per RECIST 1.1.

• Has provided written informed consent.

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

• Adequate liver, renal, hematologic, pulmonary and coagulation function.

Exclusion Criteria:

• Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapywithin 3 weeks prior to the first dose of CBX-12.

• Subjects who are currently receiving any other anticancer or investigationalagent(s).

• Clinically significant intercurrent disease.

• Active human immunodeficiency virus (HIV) infection.

• Active hepatitis B or C infection.